Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GOVX GeoVax Labs	$0.75 +1.6%	$0.81	$0.43 ▼ $11.18	$11.96M	3.27	995,843 shs	429,026 shs
PRFX PainReform	$1.41 -2.8%	$1.53	$1.25 ▼ $16.63	$2.83M	0.57	1.05 million shs	70,283 shs
TAOX Synaptogenix	$9.20 -3.8%	$0.00	$1.84 ▼ $11.98	$12.79M	1.87	437,258 shs	374,204 shs
XFOR X4 Pharmaceuticals	$3.14 +7.2%	$2.12	$1.35 ▼ $26.83	$18.18M	0.6	1.59 million shs	5.63 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GOVX GeoVax Labs	+5.87%	+11.99%	+8.01%	-18.47%	-70.40%
PRFX PainReform	+7.12%	+9.85%	+3.57%	-23.68%	+15.15%
TAOX Synaptogenix	+14.63%	+53.70%	+955,999,900.00%	+955,999,900.00%	+955,999,900.00%
XFOR X4 Pharmaceuticals	+13.79%	+85.44%	+97.97%	-2.98%	-83.86%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GOVX GeoVax Labs	2.1981 of 5 stars	3.5	2.0	0.0	0.0	3.3	0.0	0.6
PRFX PainReform	1.2507 of 5 stars	0.0	4.0	0.0	0.0	2.5	1.7	0.6
TAOX Synaptogenix	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
XFOR X4 Pharmaceuticals	4.3592 of 5 stars	3.5	2.0	0.0	4.6	2.4	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GOVX GeoVax Labs	3.00	Buy	$8.88	1,081.76% Upside
PRFX PainReform	2.00	Hold	N/A	N/A
TAOX Synaptogenix	0.00	N/A	N/A	N/A
XFOR X4 Pharmaceuticals	3.00	Buy	$71.17	2,166.45% Upside

Current Analyst Ratings Breakdown

Latest PRFX, TAOX, GOVX, and XFOR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	XFOR X4 Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$7.00 ➝ $3.50
8/7/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
7/29/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
7/17/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
6/16/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GOVX GeoVax Labs	$3.95M	3.03	N/A	N/A	$0.18 per share	4.17
PRFX PainReform	N/A	N/A	N/A	N/A	$2.08 per share	N/A
TAOX Synaptogenix	N/A	N/A	N/A	N/A	$4.33 per share	N/A
XFOR X4 Pharmaceuticals	$2.56M	7.10	N/A	N/A	$0.69 per share	4.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GOVX GeoVax Labs	-$24.99M	-$2.01	N/A	N/A	N/A	-403.88%	-408.80%	-279.89%	N/A
PRFX PainReform	-$14.59M	-$147.33	N/A	∞	N/A	N/A	N/A	N/A	8/21/2025 (Estimated)
TAOX Synaptogenix	-$12.77M	-$10.08	N/A	∞	N/A	N/A	-115.28%	-58.31%	N/A
XFOR X4 Pharmaceuticals	-$37.45M	-$14.84	N/A	N/A	N/A	-311.15%	-375.31%	-72.87%	8/14/2025 (Estimated)

Latest PRFX, TAOX, GOVX, and XFOR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/8/2025	Q2 2025	XFOR X4 Pharmaceuticals	-$4.53	-$3.47	+$1.06	-$3.47	$1.62 million	$1.97 million
7/28/2025	Q2 2025	GOVX GeoVax Labs	-$0.41	-$0.35	+$0.06	-$0.35	$0.37 million	$0.85 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GOVX GeoVax Labs	N/A	N/A	N/A	N/A	N/A
PRFX PainReform	N/A	N/A	N/A	N/A	N/A
TAOX Synaptogenix	N/A	N/A	N/A	N/A	N/A
XFOR X4 Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GOVX GeoVax Labs	N/A	2.03	2.03
PRFX PainReform	N/A	1.81	1.81
TAOX Synaptogenix	N/A	72.59	72.59
XFOR X4 Pharmaceuticals	19.10	3.19	3.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GOVX GeoVax Labs	6.09%
PRFX PainReform	37.28%
TAOX Synaptogenix	10.34%
XFOR X4 Pharmaceuticals	72.03%

Insider Ownership

Company	Insider Ownership
GOVX GeoVax Labs	1.20%
PRFX PainReform	34.40%
TAOX Synaptogenix	2.73%
XFOR X4 Pharmaceuticals	2.37%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GOVX GeoVax Labs	10	15.93 million	15.73 million	Not Optionable
PRFX PainReform	4	2.01 million	1.32 million	Not Optionable
TAOX Synaptogenix	4	1.39 million	1.35 million	N/A
XFOR X4 Pharmaceuticals	80	5.79 million	5.65 million	Optionable

PRFX, TAOX, GOVX, and XFOR Headlines

Recent News About These Companies

X4 Pharmaceuticals Closes $85M Private Placement Deal

3 hours ago | theglobeandmail.com

X4 Pharmaceuticals price target lowered to $3.50 from $7 at H.C. Wainwright

August 13 at 5:48 PM | msn.com

X4 Pharmaceuticals Stock Rises On Closing Of Upsized Offering, But Brokerage Lowers Price Target

August 13 at 5:48 PM | msn.com

X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement

August 13 at 7:00 AM | globenewswire.com

X4 Pharmaceuticals announces $60M financing, management changes

August 12 at 5:08 PM | msn.com

X4 Pharmaceuticals Announces $60M Equity Financing

August 12 at 5:08 PM | msn.com

X4 Pharmaceuticals secures $60M PIPE financing

August 12 at 5:08 PM | msn.com

X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership

August 12 at 7:00 AM | globenewswire.com

X4 Pharmaceuticals, Inc. (XFOR) - Yahoo Finance

July 3, 2025 | finance.yahoo.com

X4 Pharmaceuticals Inc News (XFOR) - Investing.com

July 2, 2025 | investing.com

XFOR X4 Pharmaceuticals, Inc. - Seeking Alpha

June 26, 2025 | seekingalpha.com

X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)

June 16, 2025 | globenewswire.com

X4 Pharmaceuticals Gets Fast Track Regulatory Designation for Neutropenia Drug

June 10, 2025 | marketwatch.com

X4 Pharmaceuticals gains on fast-track designation for mavorixafor for treatment of chronic neutropenia

June 10, 2025 | msn.com

X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA

June 10, 2025 | globenewswire.com

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 2, 2025 | globenewswire.com

X4 Pharmaceuticals Reports Positive Phase 2 Trial Results for Mavorixafor in Chronic Neutropenia, Accepted for Presentation at EHA Congress

May 16, 2025 | nasdaq.com

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress

May 14, 2025 | globenewswire.com

X4 Pharmaceuticals Inc (XFOR) Q1 2025 Earnings Call Highlights: Progress in Maverick 4 ...

May 2, 2025 | finance.yahoo.com

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2025 Earnings Call Transcript

May 2, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRFX, TAOX, GOVX, and XFOR Company Descriptions

GeoVax Labs NASDAQ:GOVX

$0.75 +0.01 (+1.62%)

As of 04:00 PM Eastern

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

PainReform NASDAQ:PRFX

$1.41 -0.04 (-2.76%)

Closing price 03:54 PM Eastern

Extended Trading

$1.42 +0.02 (+1.06%)

As of 04:14 PM Eastern

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

Synaptogenix NASDAQ:TAOX

$9.20 -0.36 (-3.77%)

As of 04:00 PM Eastern

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.

X4 Pharmaceuticals NASDAQ:XFOR

$3.14 +0.21 (+7.17%)

Closing price 04:00 PM Eastern

Extended Trading

$3.14 +0.00 (+0.16%)

As of 04:18 PM Eastern

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time